secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001213900-24-090766
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio announces Cell Reports publication showing XPro1595 promotes remyelination
--------------------------------------------------------------------------------

- Publication in Cell Reports demonstrates XPro1595 converts microglia from demyelinating to remyelinating cell.
- Study led by Hellenic Pasteur Institute; identifies solTNF as critical checkpoint for microglia polarization.
- Demyelination is core mechanism in neurodegeneration; XPro1595 targets solTNF to restore glia function.
- INmune expects top-line Phase II cognitive results in early Alzheimer's patients in first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024090766/0001213900-24-090766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024090766/ea0218672-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-090766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer